State Street Corp boosted its position in shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 8.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,653,427 shares of the biotechnology company’s stock after buying an additional 197,978 shares during the period. State Street Corp owned 3.48% of Momenta Pharmaceuticals worth $44,842,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of MNTA. BlackRock Inc. increased its stake in Momenta Pharmaceuticals by 64,825.8% during the 1st quarter. BlackRock Inc. now owns 8,774,070 shares of the biotechnology company’s stock worth $117,134,000 after buying an additional 8,760,556 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Momenta Pharmaceuticals by 322.9% during the 2nd quarter. Acadian Asset Management LLC now owns 696,138 shares of the biotechnology company’s stock worth $11,762,000 after purchasing an additional 531,525 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Momenta Pharmaceuticals by 186.4% during the 2nd quarter. Renaissance Technologies LLC now owns 797,400 shares of the biotechnology company’s stock worth $13,476,000 after purchasing an additional 519,000 shares during the last quarter. FMR LLC boosted its holdings in shares of Momenta Pharmaceuticals by 3.3% during the 2nd quarter. FMR LLC now owns 11,125,193 shares of the biotechnology company’s stock worth $188,015,000 after purchasing an additional 351,743 shares during the last quarter. Finally, Ameriprise Financial Inc. boosted its holdings in shares of Momenta Pharmaceuticals by 102.5% during the 2nd quarter. Ameriprise Financial Inc. now owns 691,778 shares of the biotechnology company’s stock worth $11,691,000 after purchasing an additional 350,112 shares during the last quarter. Institutional investors own 93.89% of the company’s stock.

In other news, President Craig A. Wheeler sold 35,667 shares of the stock in a transaction dated Thursday, September 28th. The shares were sold at an average price of $19.03, for a total transaction of $678,743.01. Following the completion of the sale, the president now owns 286,121 shares in the company, valued at $5,444,882.63. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, President Craig A. Wheeler sold 4,116 shares of the stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $15.07, for a total transaction of $62,028.12. Following the sale, the president now owns 269,231 shares of the company’s stock, valued at approximately $4,057,311.17. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 79,463 shares of company stock worth $1,411,098. Corporate insiders own 4.40% of the company’s stock.

WARNING: This news story was first posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The legal version of this news story can be viewed at https://www.watchlistnews.com/state-street-corp-boosts-holdings-in-momenta-pharmaceuticals-inc-mnta/1679951.html.

Several research analysts have recently weighed in on the company. Zacks Investment Research cut Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Barclays PLC reiterated an “equal weight” rating and issued a $16.00 price objective (down from $17.00) on shares of Momenta Pharmaceuticals in a report on Wednesday, October 4th. Stifel Nicolaus reiterated a “buy” rating and issued a $26.00 price objective on shares of Momenta Pharmaceuticals in a report on Thursday, August 3rd. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and issued a $14.00 price objective (down from $18.00) on shares of Momenta Pharmaceuticals in a report on Thursday, October 5th. Finally, BidaskClub cut Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. Three equities research analysts have rated the stock with a sell rating and nine have issued a hold rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $15.00.

Momenta Pharmaceuticals, Inc. (NASDAQ MNTA) opened at $13.20 on Friday. Momenta Pharmaceuticals, Inc. has a twelve month low of $10.75 and a twelve month high of $19.90.

Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.03. The company had revenue of $24.09 million for the quarter, compared to analyst estimates of $29.58 million. Momenta Pharmaceuticals had a negative return on equity of 16.20% and a negative net margin of 55.61%. The business’s quarterly revenue was down 17.3% compared to the same quarter last year. During the same quarter last year, the company posted ($0.26) earnings per share. sell-side analysts expect that Momenta Pharmaceuticals, Inc. will post -0.99 EPS for the current fiscal year.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Want to see what other hedge funds are holding MNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA).

Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.